Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis
The prognostic role of neutrophil to lymphocyte ratio (NLR) in gastric cancer remains controversial. We aimed to quantify the prognostic role of peripheral blood NLR in gastric cancer. A literature search was conducted in PubMed, EMBASE, and Cochrane databases. The results for overall survival (OS)...
Gespeichert in:
| Veröffentlicht in: | Disease markers 2016-01, Vol.2016 (2016), p.1-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10 |
|---|---|
| container_issue | 2016 |
| container_start_page | 1 |
| container_title | Disease markers |
| container_volume | 2016 |
| creator | Wang, Zhen-ning Gao, X.-H. Zhao, Junhua Yang, Yu-chong Huang, Xuan-zhang Song, Yong-xi Gao, Peng Chen, Xiao-wan Sun, Jing-xu Ma, Bin |
| description | The prognostic role of neutrophil to lymphocyte ratio (NLR) in gastric cancer remains controversial. We aimed to quantify the prognostic role of peripheral blood NLR in gastric cancer. A literature search was conducted in PubMed, EMBASE, and Cochrane databases. The results for overall survival (OS) and progression-free survival (PFS)/disease-free survival (DFS) are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). 19 studies with 5431 patients were eligible for final analysis. Elevated NLRs were associated with a significantly poor outcome for OS (HR = 1.98; 95% CI: 1.75–2.24, p |
| doi_str_mv | 10.1155/2016/7862469 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4746375</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A508841477</galeid><sourcerecordid>A508841477</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-e6a4282fc0f0aeb4a5f42a846d01ff50af951520379f89364514030505f63c5f3</originalsourceid><addsrcrecordid>eNqNkb9v1DAYQCMEokdhY0aWWJAg1Hb8KwvoOKAgHVQq7Wy5zueeURIfttMqO384Pt1RYGPy8D09f_arqqcEvyaE8xOKiTiRSlAm2nvVgijJayUafL9aYCpVjSnDR9WjlL5jTGjL2ofVERUtZUrSRfVzZUaUN4C-wpRj2G58j3JA63nYboKdM6Bzk31A7wBdJuh2s_eQIQ5-BHRqUo7eouKwENFFBJMHGDM6m7INA6S3aIm-zSnDUCQWncONh1tkxg59gWzq5Wj6Ofn0uHrgTJ_gyeE8ri4_frhYfarXZ6efV8t1bZkkuQZhGFXUWeywgStmuGPUKCY6TJzj2LiWE05xI1un2kYwThhuMMfcicZy1xxXb_be7XQ1QGfLqtH0ehv9YOKsg_H638noN_o63GgmmWgkL4IXB0EMPyZIWQ8-Weh7M0KYkiZStIK0lJKCPt-j16YH7UcXitHucL3kWClGmJSFerWnbAwpRXB3yxCsd3n1Lq8-5C34s78fcAf_7lmAl3tg48fO3Pr_1JU-5W7zhyblEyVrfgGr8bbK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1769619221</pqid></control><display><type>article</type><title>Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wang, Zhen-ning ; Gao, X.-H. ; Zhao, Junhua ; Yang, Yu-chong ; Huang, Xuan-zhang ; Song, Yong-xi ; Gao, Peng ; Chen, Xiao-wan ; Sun, Jing-xu ; Ma, Bin</creator><contributor>Bowne, Wilbur B.</contributor><creatorcontrib>Wang, Zhen-ning ; Gao, X.-H. ; Zhao, Junhua ; Yang, Yu-chong ; Huang, Xuan-zhang ; Song, Yong-xi ; Gao, Peng ; Chen, Xiao-wan ; Sun, Jing-xu ; Ma, Bin ; Bowne, Wilbur B.</creatorcontrib><description>The prognostic role of neutrophil to lymphocyte ratio (NLR) in gastric cancer remains controversial. We aimed to quantify the prognostic role of peripheral blood NLR in gastric cancer. A literature search was conducted in PubMed, EMBASE, and Cochrane databases. The results for overall survival (OS) and progression-free survival (PFS)/disease-free survival (DFS) are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). 19 studies with 5431 patients were eligible for final analysis. Elevated NLRs were associated with a significantly poor outcome for OS (HR = 1.98; 95% CI: 1.75–2.24, p<0.001) and PFS (HR = 1.58; 95% CI: 1.32–1.88, p<0.001) compared with patients who had normal NLRs. The NLR was higher for patients with late-stage compared with early-stage gastric cancer (OR = 2.76; 95% CI: 1.36–5.61, p=0.005). NLR lost its predictive role for patients with stage IV gastric cancer who received palliative surgery (HR = 1.73; 95% CI: 0.85–3.54, p=0.13). Our results also indicated that prognoses might be influenced by the NLR cutoff values. In conclusion, elevated pretreatment NLRs are associated with poor outcome for patients with gastric cancer. The ability to use the NLR to evaluate the status of patients may be used in the future for personalized cancer care.</description><identifier>ISSN: 0278-0240</identifier><identifier>EISSN: 1875-8630</identifier><identifier>DOI: 10.1155/2016/7862469</identifier><identifier>PMID: 26924872</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Evaluation ; Health aspects ; Health status indicators ; Humans ; Lymphocyte Count ; Lymphocytes ; Neutrophils ; Neutrophils - immunology ; Patient outcomes ; Predictive Value of Tests ; Prognosis ; Review ; Stomach cancer ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - immunology ; Survival Analysis ; Treatment Outcome</subject><ispartof>Disease markers, 2016-01, Vol.2016 (2016), p.1-10</ispartof><rights>Copyright © 2016 Jingxu Sun et al.</rights><rights>COPYRIGHT 2016 John Wiley & Sons, Inc.</rights><rights>Copyright © 2016 Jingxu Sun et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-e6a4282fc0f0aeb4a5f42a846d01ff50af951520379f89364514030505f63c5f3</citedby><cites>FETCH-LOGICAL-c471t-e6a4282fc0f0aeb4a5f42a846d01ff50af951520379f89364514030505f63c5f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746375/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746375/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26924872$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Bowne, Wilbur B.</contributor><creatorcontrib>Wang, Zhen-ning</creatorcontrib><creatorcontrib>Gao, X.-H.</creatorcontrib><creatorcontrib>Zhao, Junhua</creatorcontrib><creatorcontrib>Yang, Yu-chong</creatorcontrib><creatorcontrib>Huang, Xuan-zhang</creatorcontrib><creatorcontrib>Song, Yong-xi</creatorcontrib><creatorcontrib>Gao, Peng</creatorcontrib><creatorcontrib>Chen, Xiao-wan</creatorcontrib><creatorcontrib>Sun, Jing-xu</creatorcontrib><creatorcontrib>Ma, Bin</creatorcontrib><title>Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis</title><title>Disease markers</title><addtitle>Dis Markers</addtitle><description>The prognostic role of neutrophil to lymphocyte ratio (NLR) in gastric cancer remains controversial. We aimed to quantify the prognostic role of peripheral blood NLR in gastric cancer. A literature search was conducted in PubMed, EMBASE, and Cochrane databases. The results for overall survival (OS) and progression-free survival (PFS)/disease-free survival (DFS) are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). 19 studies with 5431 patients were eligible for final analysis. Elevated NLRs were associated with a significantly poor outcome for OS (HR = 1.98; 95% CI: 1.75–2.24, p<0.001) and PFS (HR = 1.58; 95% CI: 1.32–1.88, p<0.001) compared with patients who had normal NLRs. The NLR was higher for patients with late-stage compared with early-stage gastric cancer (OR = 2.76; 95% CI: 1.36–5.61, p=0.005). NLR lost its predictive role for patients with stage IV gastric cancer who received palliative surgery (HR = 1.73; 95% CI: 0.85–3.54, p=0.13). Our results also indicated that prognoses might be influenced by the NLR cutoff values. In conclusion, elevated pretreatment NLRs are associated with poor outcome for patients with gastric cancer. The ability to use the NLR to evaluate the status of patients may be used in the future for personalized cancer care.</description><subject>Evaluation</subject><subject>Health aspects</subject><subject>Health status indicators</subject><subject>Humans</subject><subject>Lymphocyte Count</subject><subject>Lymphocytes</subject><subject>Neutrophils</subject><subject>Neutrophils - immunology</subject><subject>Patient outcomes</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Review</subject><subject>Stomach cancer</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - immunology</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0278-0240</issn><issn>1875-8630</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>EIF</sourceid><recordid>eNqNkb9v1DAYQCMEokdhY0aWWJAg1Hb8KwvoOKAgHVQq7Wy5zueeURIfttMqO384Pt1RYGPy8D09f_arqqcEvyaE8xOKiTiRSlAm2nvVgijJayUafL9aYCpVjSnDR9WjlL5jTGjL2ofVERUtZUrSRfVzZUaUN4C-wpRj2G58j3JA63nYboKdM6Bzk31A7wBdJuh2s_eQIQ5-BHRqUo7eouKwENFFBJMHGDM6m7INA6S3aIm-zSnDUCQWncONh1tkxg59gWzq5Wj6Ofn0uHrgTJ_gyeE8ri4_frhYfarXZ6efV8t1bZkkuQZhGFXUWeywgStmuGPUKCY6TJzj2LiWE05xI1un2kYwThhuMMfcicZy1xxXb_be7XQ1QGfLqtH0ehv9YOKsg_H638noN_o63GgmmWgkL4IXB0EMPyZIWQ8-Weh7M0KYkiZStIK0lJKCPt-j16YH7UcXitHucL3kWClGmJSFerWnbAwpRXB3yxCsd3n1Lq8-5C34s78fcAf_7lmAl3tg48fO3Pr_1JU-5W7zhyblEyVrfgGr8bbK</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Wang, Zhen-ning</creator><creator>Gao, X.-H.</creator><creator>Zhao, Junhua</creator><creator>Yang, Yu-chong</creator><creator>Huang, Xuan-zhang</creator><creator>Song, Yong-xi</creator><creator>Gao, Peng</creator><creator>Chen, Xiao-wan</creator><creator>Sun, Jing-xu</creator><creator>Ma, Bin</creator><general>Hindawi Publishing Corporation</general><general>John Wiley & Sons, Inc</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160101</creationdate><title>Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis</title><author>Wang, Zhen-ning ; Gao, X.-H. ; Zhao, Junhua ; Yang, Yu-chong ; Huang, Xuan-zhang ; Song, Yong-xi ; Gao, Peng ; Chen, Xiao-wan ; Sun, Jing-xu ; Ma, Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-e6a4282fc0f0aeb4a5f42a846d01ff50af951520379f89364514030505f63c5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Evaluation</topic><topic>Health aspects</topic><topic>Health status indicators</topic><topic>Humans</topic><topic>Lymphocyte Count</topic><topic>Lymphocytes</topic><topic>Neutrophils</topic><topic>Neutrophils - immunology</topic><topic>Patient outcomes</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Review</topic><topic>Stomach cancer</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - immunology</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Zhen-ning</creatorcontrib><creatorcontrib>Gao, X.-H.</creatorcontrib><creatorcontrib>Zhao, Junhua</creatorcontrib><creatorcontrib>Yang, Yu-chong</creatorcontrib><creatorcontrib>Huang, Xuan-zhang</creatorcontrib><creatorcontrib>Song, Yong-xi</creatorcontrib><creatorcontrib>Gao, Peng</creatorcontrib><creatorcontrib>Chen, Xiao-wan</creatorcontrib><creatorcontrib>Sun, Jing-xu</creatorcontrib><creatorcontrib>Ma, Bin</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Disease markers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Zhen-ning</au><au>Gao, X.-H.</au><au>Zhao, Junhua</au><au>Yang, Yu-chong</au><au>Huang, Xuan-zhang</au><au>Song, Yong-xi</au><au>Gao, Peng</au><au>Chen, Xiao-wan</au><au>Sun, Jing-xu</au><au>Ma, Bin</au><au>Bowne, Wilbur B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis</atitle><jtitle>Disease markers</jtitle><addtitle>Dis Markers</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>2016</volume><issue>2016</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0278-0240</issn><eissn>1875-8630</eissn><abstract>The prognostic role of neutrophil to lymphocyte ratio (NLR) in gastric cancer remains controversial. We aimed to quantify the prognostic role of peripheral blood NLR in gastric cancer. A literature search was conducted in PubMed, EMBASE, and Cochrane databases. The results for overall survival (OS) and progression-free survival (PFS)/disease-free survival (DFS) are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). 19 studies with 5431 patients were eligible for final analysis. Elevated NLRs were associated with a significantly poor outcome for OS (HR = 1.98; 95% CI: 1.75–2.24, p<0.001) and PFS (HR = 1.58; 95% CI: 1.32–1.88, p<0.001) compared with patients who had normal NLRs. The NLR was higher for patients with late-stage compared with early-stage gastric cancer (OR = 2.76; 95% CI: 1.36–5.61, p=0.005). NLR lost its predictive role for patients with stage IV gastric cancer who received palliative surgery (HR = 1.73; 95% CI: 0.85–3.54, p=0.13). Our results also indicated that prognoses might be influenced by the NLR cutoff values. In conclusion, elevated pretreatment NLRs are associated with poor outcome for patients with gastric cancer. The ability to use the NLR to evaluate the status of patients may be used in the future for personalized cancer care.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>26924872</pmid><doi>10.1155/2016/7862469</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0240 |
| ispartof | Disease markers, 2016-01, Vol.2016 (2016), p.1-10 |
| issn | 0278-0240 1875-8630 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4746375 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | Evaluation Health aspects Health status indicators Humans Lymphocyte Count Lymphocytes Neutrophils Neutrophils - immunology Patient outcomes Predictive Value of Tests Prognosis Review Stomach cancer Stomach Neoplasms - drug therapy Stomach Neoplasms - immunology Survival Analysis Treatment Outcome |
| title | Can the Neutrophil to Lymphocyte Ratio Be Used to Determine Gastric Cancer Treatment Outcomes? A Systematic Review and Meta-Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A46%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Can%20the%20Neutrophil%20to%20Lymphocyte%20Ratio%20Be%20Used%20to%20Determine%20Gastric%20Cancer%20Treatment%20Outcomes?%20A%20Systematic%20Review%20and%20Meta-Analysis&rft.jtitle=Disease%20markers&rft.au=Wang,%20Zhen-ning&rft.date=2016-01-01&rft.volume=2016&rft.issue=2016&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0278-0240&rft.eissn=1875-8630&rft_id=info:doi/10.1155/2016/7862469&rft_dat=%3Cgale_pubme%3EA508841477%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1769619221&rft_id=info:pmid/26924872&rft_galeid=A508841477&rfr_iscdi=true |